Abstract

Neurological long-term sequelae are increasingly considered an important challenge in the recent COVID-19 pandemic. However, most evidence for neurological symptoms after SARS-CoV-2 infection and central nervous system invasion of the virus stems from individuals severely affected in the acute phase of the disease. Here, we report long-lasting cognitive impairment along with persistent cerebrospinal fluid anti-SARS-CoV-2 antibodies in a female patient with unremarkable standard examination 6 months after mild COVID-19, supporting the implementation of neuropsychological testing and specific cerebrospinal fluid investigation also in patients with a relatively mild acute disease phase.

Details

Title
Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19
Author
Borsche Max 1 ; Reichel, Dirk 2 ; Fellbrich Anja 3 ; Lixenfeld, Anne S 4 ; Rahmöller Johann 5 ; Eva-Juliane, Vollstedt 6 ; Bandik, Föh 7 ; Balck, Alexander 1 ; Klein, Christine 6 ; Ehlers, Marc 4 ; Moser, Andreas 8   VIAFID ORCID Logo 

1  University of Lübeck, Institute of Neurogenetics, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672); University of Lübeck and University Medical Center of Schleswig-Holstein, Campus Lübeck, Department of Neurology, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672) 
2  Outpatient Practice for Neurology and Psychiatry, Lübeck, Germany (GRID:grid.4562.5) 
3  University of Lübeck and University Medical Center of Schleswig-Holstein, Campus Lübeck, Department of Neurology, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672) 
4  University of Lübeck and University Medical Center of Schleswig-Holstein, Institute of Nutritional Medicine, Lübeck, Germany (GRID:grid.4562.5) 
5  University of Lübeck and University Medical Center of Schleswig-Holstein, Institute of Nutritional Medicine, Lübeck, Germany (GRID:grid.4562.5); University of Lübeck and University Medical Center of Schleswig-Holstein, Department of Anesthesiology and Intensive Care, Lübeck, Germany (GRID:grid.4562.5) 
6  University of Lübeck, Institute of Neurogenetics, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672) 
7  University of Lübeck and University Medical Center of Schleswig-Holstein, Institute of Nutritional Medicine, Lübeck, Germany (GRID:grid.4562.5); University Medical Center Schleswig-Holstein, Campus Lübeck, Department of Medicine I, Lübeck, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097) 
8  University of Lübeck and University Medical Center of Schleswig-Holstein, Campus Lübeck, Department of Neurology, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672); University of Lübeck, Center of Brain, Behavior and Metabolism, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672) 
Publication year
2021
Publication date
Jan 2021
Publisher
Springer Nature B.V.
e-ISSN
25243489
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/s42466-021-00135-y
ProQuest document ID
2543248107
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.